ResMedMEX:RMD 99 ROE % is 24.91% as of Mar. 2026, which is 13% above its 10-year median of 22.09. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,298.64 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 799 Medical Devices & Instruments companies, ResMed ranks better than 94.74% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. ResMed's annualized net income for the quarter that ended in Mar. 2026 was MXN28,761 Mil. ResMed's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was MXN115,439 Mil. Therefore, ResMed's annualized ROE % for the quarter that ended in Mar. 2026 was 24.91%.
The historical rank and industry rank for ResMed's ROE % or its related term are showing as below:
MEX:RMD'
s ROE % Range Over the Past 10 Years
Min: 15.7 Med: 22.09 Max: 27.21
Current: 24.95
During the past 13 years, ResMed's highest ROE % was 27.21%. The lowest was 15.70%. And the median was 22.09%.
MEX:RMD's ROE % is ranked better than 94.74% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs MEX:RMD: 24.95
ResMed (MEX:RMD) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
ResMed ROE % Related Terms
ResMed ROE % Historical Data
* Premium members only.
The historical data trend for ResMed's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, ResMed's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's ROE % distribution charts can be found below:
* The bar in red indicates where ResMed's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
ResMed (MEX:RMD) has a ROE % of 24.91% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ResMed and its competitors. This is 13% above median its historical median of 22.09. Over the past decade, ResMed's ROE % has ranged from 15.70 to 27.21. According to the industry distribution chart, ResMed ranks #42 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 5.3%.
Is ResMed's ROE % too high?
ResMed's current ROE % of 24.91% is 13% above median its 10-year median of 22.09. Over the past 10 years, this metric has ranged from a low of 15.70 to a high of 27.21. The Medical Devices & Instruments industry median ROE % is 2.42. ResMed's value of 24.91% is 929.3% above this industry median. Based on the distribution chart, ResMed ranks #42 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ResMed has a GF Score™ of 99/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's ROE % compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #42 out of 799 companies for ROE %. This places ResMed in the top 5% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. ResMed's value of 24.91% is 929.3% above this benchmark. Historically, ResMed's own ROE % has ranged from 15.70 to 27.21 over the past decade. While the company's 10-year median is 22.09 vs. the industry median of 2.42, ResMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current ROE % of 24.91% is 929.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current ROE % is 24.91%, which is 13% above median its own 10-year median of 22.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN5,298.64, compared to a current price of MXN3,716.10 — trading 29.9% below its estimated fair value. The current ROE % is 24.91%, which is 13% above median its 10-year median of 22.09 and 929.3% above the Medical Devices & Instruments industry median of 2.42. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For ResMed (MEX:RMD), the current ROE % is 24.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (MEX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of MXN3,716.10 is trading 29.9% below its estimated GF Value™ of MXN5,298.64.
GuruFocus considers ResMed to be Significantly Undervalued.
Key valuation signals for MEX:RMD:
ROE %: 24.91% (13% above median its 10-year median of 22.09)
GF Value™: MXN5,298.64 vs. price of MXN3,716.10 (29.9% below fair value)
Industry Position: 929.3% above the Medical Devices & Instruments median (#42 of 799)
No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score
Get the complete analysis for MEX:RMD
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RMD has been successfully added to your 
